Evolution of ramucirumab in the treatment of cancer – A review of literature

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

(2015) E. G. Chiorean et al.   ANNALS OF ONCOLOGY

A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer

(2015) Maha Hussain et al.   EUROPEAN JOURNAL OF CANCER

Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer

(2015) John R. Mackey et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

(2015) Andrew X Zhu et al.   LANCET ONCOLOGY

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

(2014) Jorge A. Garcia et al.   CANCER

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

(2014) Robert C. Doebele et al.   CANCER

A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma

(2014) Richard D. Carvajal et al.   EUROPEAN JOURNAL OF CANCER

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

(2014) Richard T. Penson et al.   GYNECOLOGIC ONCOLOGY

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

(2014) D. Ross Camidge et al.   Journal of Thoracic Oncology

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway

(2014) Xi Chen et al.   NATURE

An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer

(2014) R. Garcia-Carbonero et al.   ONCOLOGIST

Mechanisms of resistance to anti-angiogenesis therapies

(2013) Sandy Giuliano et al.   BIOCHIMIE

Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations

(2013) E. M. Lindholm et al.   CLINICAL CANCER RESEARCH

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

(2013) A. X. Zhu et al.   CLINICAL CANCER RESEARCH

Targeted inhibition of VEGF receptor 2: an update on ramucirumab

(2013) Jeffrey Melson Clarke et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY